548 related articles for article (PubMed ID: 33191806)
1. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis.
Williams KA; Roh YS; Brown I; Sutaria N; Bakhshi P; Choi J; Gabriel S; Chavda R; Kwatra SG
Expert Rev Clin Pharmacol; 2021 Jan; 14(1):67-77. PubMed ID: 33191806
[No Abstract] [Full Text] [Related]
2. Prurigo nodularis: Epidemiology and clinical features.
Huang AH; Williams KA; Kwatra SG
J Am Acad Dermatol; 2020 Dec; 83(6):1559-1565. PubMed ID: 32454098
[TBL] [Abstract][Full Text] [Related]
3. A critical review of dupilumab for adult patients with prurigo nodularis.
Biazus Soares G; Yosipovitch G
Expert Rev Clin Immunol; 2024 Mar; 20(3):249-254. PubMed ID: 37811660
[TBL] [Abstract][Full Text] [Related]
4. A critical evaluation of nemolizumab for prurigo nodularis.
Brooks SG; Yosipovitch G
Expert Rev Clin Immunol; 2024 Jun; 20(6):577-587. PubMed ID: 38217530
[TBL] [Abstract][Full Text] [Related]
5. INDIVIDUAL ARTICLE: Management of Prurigo Nodularis.
Elmariah SB; Tao L; Valdes-Rodriguez R; Laquer V
J Drugs Dermatol; 2023 Dec; 22(12):SF365502s15-SF365502s22. PubMed ID: 38051855
[TBL] [Abstract][Full Text] [Related]
6. Prurigo nodularis: a physician survey to evaluate current perceptions of its classification, clinical experience and unmet need.
Pereira MP; Basta S; Moore J; Ständer S
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2224-2229. PubMed ID: 29869425
[TBL] [Abstract][Full Text] [Related]
7. Prurigo nodularis: new insights into pathogenesis and novel therapeutics.
Liao V; Cornman HL; Ma E; Kwatra SG
Br J Dermatol; 2024 May; 190(6):798-810. PubMed ID: 38345154
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic Workup and Evaluation of Patients with Prurigo Nodularis.
Kwon CD; Khanna R; Williams KA; Kwatra MM; Kwatra SG
Medicines (Basel); 2019 Sep; 6(4):. PubMed ID: 31561504
[TBL] [Abstract][Full Text] [Related]
9. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus.
Elmariah S; Kim B; Berger T; Chisolm S; Kwatra SG; Mollanazar N; Yosipovitch G
J Am Acad Dermatol; 2021 Mar; 84(3):747-760. PubMed ID: 32682025
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of pruritus in prurigo nodularis.
Shao Y; Wang D; Zhu Y; Xiao Z; Jin T; Peng L; Shen Y; Tang H
Front Immunol; 2023; 14():1301817. PubMed ID: 38077377
[TBL] [Abstract][Full Text] [Related]
11. Prurigo nodularis: a benign dermatosis derived from a persistent pruritus.
Vaidya DC; Schwartz RA
Acta Dermatovenerol Croat; 2008; 16(1):38-44. PubMed ID: 18358109
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of biologics in prurigo nodularis.
Müller S; Bieber T; Ständer S
Expert Opin Biol Ther; 2022 Jan; 22(1):47-58. PubMed ID: 34289753
[TBL] [Abstract][Full Text] [Related]
13. Prurigo Nodularis: Review and Emerging Treatments.
Leis M; Fleming P; Lynde CW
Skin Therapy Lett; 2021 May; 26(3):5-8. PubMed ID: 34077168
[TBL] [Abstract][Full Text] [Related]
14. REMOVED: Plasma Steroids and Endocannabinoids Used as Biomarkers to Assess the Pruritus Severity of Patients With Prurigo Nodularis.
Chu L; Wang LK; Wu Y; Yang H; Wang W; Lu Q; Deng H
Actas Dermosifiliogr; 2022 Mar; 113(3):244-253. PubMed ID: 35282859
[TBL] [Abstract][Full Text] [Related]
15. Treatment of prurigo nodularis with lenalidomide.
Ossorio-García L; Jiménez-Gallo D; Rodríguez-Mateos ME; Arjona-Aguilera C; Linares-Barrios M
Dermatol Ther; 2017 Mar; 30(2):. PubMed ID: 27891738
[TBL] [Abstract][Full Text] [Related]
16. Prurigo nodularis: Pathogenesis and management.
Williams KA; Huang AH; Belzberg M; Kwatra SG
J Am Acad Dermatol; 2020 Dec; 83(6):1567-1575. PubMed ID: 32461078
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
[TBL] [Abstract][Full Text] [Related]
18. Dupilumab as promising treatment for prurigo nodularis: current evidences.
Toffoli L; Farinazzo E; Zelin E; Agozzino M; Dianzani C; Di Meo N; Nan K; Zalaudek I; Conforti C
J Dermatolog Treat; 2022 May; 33(3):1306-1311. PubMed ID: 33588666
[TBL] [Abstract][Full Text] [Related]
19. The impact of prurigo nodularis on quality of life: a systematic review and meta-analysis.
Janmohamed SR; Gwillim EC; Yousaf M; Patel KR; Silverberg JI
Arch Dermatol Res; 2021 Oct; 313(8):669-677. PubMed ID: 33108524
[TBL] [Abstract][Full Text] [Related]
20. [Psychosomatic aspects of prurigo nodularis].
Schneider G; Hockmann J; Stumpf A
Hautarzt; 2014 Aug; 65(8):704-8. PubMed ID: 25113329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
